NR1H4 and primary biliary cholangitis: At present, FXR agonists are in Phase II and III clinical trials for nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PBC), and primary biliary cirrhosis (PSC)24.